Jubilant Ingrevia Limited has announced the commencement of commercial production at its Bharuch facility through its wholly owned subsidiary, Jubilant Agro Sciences Limited. The production milestone was achieved on March 21, 2026, as disclosed under Regulation 30 of SEBI Listing Regulations.

Production Details

The subsidiary has begun commercial production of agro intermediates at the Bharuch facility as part of a Contract Development and Manufacturing Organization (CDMO) contract with a leading agrochemical company. This development represents a significant step in the company's manufacturing operations at the Bharuch site.

Operational Milestone

The company has confirmed that material dispatch from the facility commenced on March 21, 2026, indicating the operational readiness of the production line. This marks the transition from the setup phase to active commercial operations at the Bharuch facility.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and follows the guidelines outlined in SEBI Master Circular No: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure ensures transparency regarding material developments in the company's operations.

Strategic Partnership

The CDMO contract with a leading agrochemical company demonstrates Jubilant Ingrevia's capabilities in contract manufacturing services. This partnership allows the subsidiary to leverage its manufacturing expertise while serving the requirements of established players in the agrochemical sector.

Jubilant Ingrevia Limited has announced the acquisition of 100% stake in Remidex Pharma Private Limited for 165 Million Rupees, marking a strategic expansion into the human nutrition premixes market. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations.

Acquisition Details

The acquisition will be completed through a Share Purchase Agreement, making Remidex a wholly owned subsidiary of Jubilant Ingrevia Limited. The transaction involves cash consideration and is subject to customary closing conditions.

About Remidex Pharma

Remidex Pharma Private Limited, incorporated on June 15, 1981, operates from Bangalore and specializes in manufacturing micronutrient premixes and nutraceuticals. The company also functions as a contract manufacturing organization for leading Indian and multinational pharmaceutical companies.

Financial Performance

Remidex has demonstrated consistent revenue generation over the past three years:

Strategic Rationale

The acquisition aligns with Jubilant Ingrevia's strategy to advance in the value chain towards premixes in the human nutrition space. This move builds upon the company's existing leadership position in Vitamins B3 and B4, expanding its capabilities in the human nutrition industry.

Remidex operates one of the top manufacturing facilities for multivitamin premixes used in nutritional and food products. The Bangalore-based facility holds key certifications including WHO-GMP, FSSC, and FSSAI, ensuring high-grade manufacturing standards.

Market Position

Remidex is recognized as one of the leading players in the human nutrition industry, with strong presence in multivitamin premixes manufacturing and marquee customer base across Indian and multinational pharmaceutical organizations. The company maintains robust innovation and quality control capabilities with comprehensive certifications for pharmaceutical manufacturing.

The acquisition represents a non-related party transaction, with no promoter or group company interest in the target entity. The transaction is expected to strengthen Jubilant Ingrevia's position in the growing human nutrition and pharmaceutical manufacturing sectors.